Skip to content

In the BioHarmony Drug Report Database

Acalabrutinib

Calquence (acalabrutinib) is a small molecule pharmaceutical. Acalabrutinib was first approved as Calquence on 2017-10-31. It is used to treat mantle-cell lymphoma in the USA. It has been approved in Europe to treat b-cell chronic lymphocytic leukemia. The pharmaceutical is active against tyrosine-protein kinase BTK. In addition, it is known to target tyrosine-protein kinase Fyn, receptor tyrosine-protein kinase erbB-2, epidermal growth factor receptor, tyrosine-protein kinase Blk, tyrosine-protein kinase JAK3, tyrosine-protein kinase ITK/TSK, proto-oncogene tyrosine-protein kinase Src, cytoplasmic tyrosine-protein kinase BMX, tyrosine-protein kinase Tec, tyrosine-protein kinase TXK, tyrosine-protein kinase Lyn, tyrosine-protein kinase Lck, and receptor tyrosine-protein kinase erbB-4. Calquence's patents are valid until 2036-07-01 (FDA).
Trade Name Calquence
Common Name Acalabrutinib
Indication b-cell chronic lymphocytic leukemia, mantle-cell lymphoma
Drug Class Tyrosine kinase inhibitors: Bruton's (Btk) inhibitors
Acalabrutinib
Get full access now